Introduction
Hematopoietic SCT (HSCT) has been a successful therapy in use since the 1960s and a proven cure for pediatric patients suffering from hematological disorders as well as immune deficiencies and metabolic disorders. For many of these children, SCT is the only curative option.
Despite advances in donor HLA-typing methods (and thus donor selection) and post transplant immune suppression, acute GvHD (aGvHD) remains a significant cause of transplant-related mortality and morbidity following allogeneic HSCT, even in the matched HLA-identical sibling setting. 1, 2 Billingham, in his historic Harvey Lecture, described the fundamentals of aGvHD over 30 years ago. 3 The first requirement is that the graft must contain sufficient numbers of immunologically competent cells. Second, the host must have important transplant isoantigens lacking in the graft. Finally, the host immune system must be incapable of mounting an effective immune response against the graft.
Acute GvHD occurs most frequently after engraftment, and this has led to an arbitrary period of 100 days post HSCT that has defined the acute versus chronic manifestation of this disease. However, as transplant practice has changed, so too has the timing of GvHD occurrence, and clinical manifestations are now a better definition than timing alone. The use of non-myeloablative or so-called reduced-intensity conditioning regimens has reduced the hematological toxicities of allogeneic HSCT, but GvHD remains a problem. 4, 5 Donor lymphocyte infusions, especially in the context of reduced-intensity HSCT, are becoming more commonplace in protocols designed to induce graft versus leukemia effect and treat relapse or mixed chimeric populations after HSCT. [6] [7] [8] [9] [10] These strategies are associated with the risk of inducing GvHD. Clinical manifestations depend on the degree of donor/recipient HLA incompatibility and graft alloreactivity to major host antigens. The primary organs affected in the acute process are skin, liver and gastrointestinal (GI) tract, although other sites may be affected.
The aim of this review is to update the most recent knowledge of pathophysiology and clinical manifestations of aGvHD.
Genetic basis of GvHD
HLA-dependent factors 1. Major incompatibility antigens have a major effect on the biology and occurrence of GvHD in the HSCT setting. The encoding loci, so-called MHC, have a central role in both humoral and cell-mediated immune responses. MHC is located on the short arm of chromosome 6 (p21) and encodes for HLA. Class I and II HLAs are cell surface molecules that not only determine histocompatibility but also control T-cell recognition. 11, 12 Class I (HLA-A, B and C) are expressed on all nucleated cells. Sibling donors and recipients who share HLA antigens have better engraftment and reduced rates and severity of GvHD. 13 Class II (DR, DQ and DP) are more selectively expressed on cells of the immune system. CD4 þ T cells are able to recognize foreign antigens through the presentation of class II HLA molecules. Class II HLA is found abundantly in skin and GI tract epithelium and may contribute to the specific organ sites of aGvHD. 11, 14 2. mHAs are peptides derived from intracellular proteins presented by specific MHC molecules to donor T cells. 15 These minor antigens express genetic polymorphisms encoded by a wide range of genes and are important in the initiation of GvHD in the identical sibling and sex-mismatched allogeneic transplant setting. 16 Human mHAs are mostly, but not exclusively, restricted to class I HLA. Tissue expression of some mHAs is limited to the hematopoietic system (HA-1 and HA-2), whereas other minor antigens are more widely expressed (HA-Y and HA-3). Mismatches between donor and recipient for HA-1, HA-2 and HA-5 are associated with an increased risk of GvHD. 17 Non-HLA-dependent factors 1. Cytokine gene polymorphisms. Cytokine gene polymorphisms may have an important role in the afferent phase of aGvHD. Studies suggest that high levels of tumornecrosis factor a (TNF-a) and low levels of IL-10 in patients pre-transplant result in more GvHD. These results, in turn, correlate with further investigations into the gene polymorphisms of TNF-a and IL-10 in donor and recipient HSCT cohorts. Candidate gene polymorphisms, which have been linked to the risk of aGvHD, that have so far been described are TNF-a, IL-10, IL-6, IFN-g, the IL-1 family and transforming growth factor b genes. 17 Other candidate genes are Th1 and Th2 associated with immunopathology of GvHD, for example, IL-2, IL-13 and IL-4. It is important to interpret these genetic polymorphisms and their roles in GvHD susceptibility, as the relevance of these polymorphisms varies depending upon the donor, recipient and stem cell source (see Table 1 ). As more knowledge is available from gene mapping of the pro-and anti-inflammatory genes, the influence of polymorphisms of neighboring genes and the effects of cytokine release on the outcome of HSCT, interpretation will undoubtedly become more complex.
2. NOD2/CARD15 polymorphisms. The NOD2/ CARD15 gene is involved in the innate immune response to bacterial infections in the GI tract and mediates nuclear factor-kB activation in response to bacterial cell wall products. Three single-nucleotide polymorphisms (8, 12 and 13) in the NOD2/CARD15 gene have been associated with a diminished nuclear factor-kB production and were first described with an increased risk of acute inflammatory bowel disease (Crohn's disease). 18 Recently, the same single-nucleotide polymorphisms have been implicated in both the incidence and severity of a GvHD following HLA-identical sibling donor HSCT. Transplant-related mortality rose from a cumulative incidence of 20% at 1 year post transplant for donor/recipient pairs without mutations to 49% for those with a recipient mutation to Table 1 GvHD risk related to donor/recipient cytokine gene polymorphisms 59% for transplants with a donor-only mutation, whereas the worst-case scenario was where both donor and recipient had detectable single-nucleotide polymorphism mutations of the NOD/CARD15 gene (83%). Similar incidences were seen for overall and severe GI GvHD, which were prominent in matched sibling identical transplants. 19, 20 These results have been demonstrated in patients undergoing T-cell-depleted donor grafts, suggesting that the detrimental effect of the NOD/CARD15 gene polymorphism is produced via the innate rather than the adaptive immune system. 21 3. Gene expression profiles. Recently, the development of high-throughput methodologies, such as single-nucleotide polymorphism arrays, has enabled the analysis of hundreds of thousands of genetic markers throughout the genome and copy number variations. 22 Gene expression profiling, using quantitative PCR methodology, of CD4 þ and CD8 þ T cells from donors has been undertaken in an attempt to identify those donors who may present a greater risk of inducing GvHD (strong alloreactive type). 23 Analysis of a cohort of patients undergoing allogeneic identical sibling HSCT, controlled for conditioning and post transplant immune suppression, elucidated a donor gene expression profile, which had a dominant influence on the occurrence of both acute and chronic GvHD in the recipient. The authors suggested that predictive models limited to a set of 10-20 genes could achieve approximately 80% accuracy and the robustness desired for donor selection. However, before such selection criteria could be used to select suitable donors and modify post transplant immune suppression, extensive validation would be required in a large number of donor-recipient pairs and in alternative donor as well and non-myeloablative stem cells transplants. 22, 23 Similarly, polymorphisms influencing the pharmocokinetics of the widely used immuno-suppressive drug methotrexate have been implicated in the occurrence of aGvHD. Two recent studies have detected associations between MTHFR (methylenetetrahydrofolate reductase) 677 T and thymidylate synthase genotypes with a reduced rate of GvHD, possibly reflecting the increased sensitivity to methotrexate associated with these alleles. 24, 25 Pathophysiology of GvHD GvHD can be described as a three-phase process. 1. Afferent phase. In this stage, as is seen with the conditioning of the patient, prior disease and comorbidity of the patient, damage to host tissue occurs (see Figure 1) . For example, bacterial endotoxins (lipopolysaccharides) may translocate from the intestinal lumen into the circulation and induce the release of inflammatory cytokines, including IL-1, TNF-a, IL-6 and IFN-g. [26] [27] [28] These act to upregulate the expression of MHC antigens and cell surface adhesion molecules on host APCs, which mediate an alloimmune response by mature donor T cells. This 'cytokine storm' is an important mediator of the occurrence and severity of aGvHD, and the abovementioned polymorphism of cytokine genes directly influences this scenario. However, the balance between pro-and anti-inflammatory cytokine release in determining GvHD is complex and most probably influenced by many transplant variables including the type of conditioning regimen, stem cell source and number of T cells within the graft as well as the type of GvHD prophylaxis. This is illustrated in a recent study of 113 patients undergoing non-myeloablative HSCT, where an increase of circulating IL-12 but no other cytokines was strongly associated with the development of aGvHD. 29 This is in sharp contrast to patients undergoing myeloablative conditioning, suggesting that the pathogenesis of GvHD is different in these two settings.
2. Induction and expansion phase. The second step is the triggering and activation of donor-derived T cells by recipient and donor APC as well as the inflammatory cytokines. 9 Activated T cells result in the production of IL-2 and IFN-g (or Th1 response). 30 IL-2 controls and amplifies the allogeneic immune response, 31 activating further T-cell and natural killer cell responses, priming macrophages to release TNF-a and further inflammation damages skin and gut.
3. Effector phase. Finally, the effector phase is characterized by activated donor T-cell-mediated cytotoxic damage against host cells through Fas-Fas ligand interaction, 32, 33 perforin-granzyme 33 and TNF-a. 34 The latter has a central role in the pathophysiology, stimulating cytokine production (IL-1, IL-6, IL-10, IL-12 and TNF-a). This dysregulation leads to the clinical manifestations of aGvHD. 1, 28, 35 Cells involved in GvHD 1. T-cell subsets. It has been shown that CD4 þ T cells are crucial for maintaining the expansion of CD8 þ T cells that mediate GvHD. 36, 37 However, in a recent clinical trial, attempts to reduce GvHD by eliminating CD8 þ cells from the graft paradoxically showed a greater incidence of fever and rash and grade 2-4 GvHD. 38 These data suggest that although CD8 þ cells are likely mediators of GvHD, CD4 þ cells also have a crucial role in the pathogenesis of the disease.
2. T-regulatory cells (CD4 þ /CD25 þ T reg ). T cells that may be capable of suppressing alloreactivity in the HSCT setting have been a recent focus of interest. A subset of CD4 þ cells that coexpress CD25 is believed to suppress alloreactivity in a contact-dependent manner, with possible roles in cytokine production including IL-10 and transforming growth factor b. 39 Although murine models have demonstrated that infusing donor grafts rich in CD4 þ CD25 þ T reg cells decreases the incidence of severe GvHD, 40 it has proven difficult to exploit this in clinical practice. This is mainly due to the fact that CD25 expression is also upregulated in the setting of alloreactive T-cell stimulation. As such, two recent studies aimed at measuring the population of CD4 þ CD25 þ T cells infused in the graft showed a direct correlation between the quantity of these cells infused and the incidence of aGvHD and cGvHD. Further characterization and a better understanding of the role of this specific subset of T cells may assist in future therapies aimed at reducing GvHD. 41, 42 3. APCs. Recent studies have also implicated the role of residual host APCs in the initiation phase of aGvHD as described in murine models. In a model where donor CD8 þ T cells recognized recipient minor HLA antigens, residual host APCs were essential for the initiation of GvHD. 20 It has also been demonstrated that the localization in various tissues may be relevant to the organ-specific manifestations of GvHD. [43] [44] [45] However, their precise role in the clinical setting in humans remains to be determined.
4. Natural killer cells. Natural killer cells can contribute to tissue damage in the effector phase by the release of inflammatory cytokines and nitric oxide. However, natural killer cells mediated cell death by two important contactdependent pathways: Fas-Fas-ligand-mediated apoptosis and perforin-granzyme-B-mediated cytolysis. 32, 33, 46 Although they are important pathways of effective cell-mediated cytotoxicity, they are not the only mechanisms involved in GvHD. Murine models using anti-Fas antibodies or perforin-deficient T cells, where the induced organ-specific changes associated with aGvHD were not pronounced, suggest that natural killer cells are more likely to have a role in the affector than the effector phase.
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Trafficking of alloreactive T cells to target organs
To induce GvHD, alloreactive T cells must migrate to the specific tissue where they can exert their effector function. Migration of immune cells is regulated by a complex system of chemokines and their receptors. The elevated expression of a number of pro-inflammatory chemokines has been demonstrated in target organs of GvHD in various murine models. 47 Their expression is influenced by the conditioning regimen as well as genetic factors and can be amplified by the occurrence of GvHD. 47 Most recently, the involvement of CCL27/CTACK-CCR10 interaction in recruiting T cells to the skin was demonstrated in 15 pediatric patients with skin GvHD. 48 During GvHD, circulating T cells isolated from these patients demonstrated a high proportion of CD4 þ CD10 þ T cells, which disappeared upon resolution of the skin GvHD. They expressed, in addition, skin homing markers (cutaneous lymphoid-associated antigen and CCR4) and produced Th1 cytokines, that is TNF-a and IL-2. These cells were absent in patients without skin GvHD. Skin biopsies showed infiltration of these cells and correlated with an increased epidermal expression of the ligand for CCL27/CTACK-CCR10. 48 
Predictors of GvHD
HLA differences between donor and recipient are the major predictor of GvHD. 49 Other factors implicated include age, 50 gender mismatch between donor and recipient, 50 mHA in otherwise identical HSCT, 16 donor age, 51 source and dose of stem cells (PBSCT greater risk than BM), 52 intensity of conditioning and GvHD prophylaxis. 53 Administration of unmanipulated doses of donor lymphocytes (so-called DLI) has an increased risk of GvHD, especially following reduced-intensity conditioning for the treatment of mixed chimerism or relapse of solid tumors. [5] [6] [7] [8] [9] Again, this is related to dose and timing following HSCT.
Consideration has been given to an index of post transplant factors that may predict the severity of GvHD, 54 and new insights are being evaluated to determine what role, if any, genetic screening may have in the risk assessment of donor and recipient pairs.
Clinical manifestations of aGvHD
Acute GvHD affects predominately affects the skin, upper and lower GI tract, liver and occasionally the eye and oral mucosa. Clinical grading is determined by the site and severity of the manifestation (see Tables 2 and 3) . 55 Biopsy of involved tissues, although lacking sensitivity, when positive may be helpful in confirming the diagnosis, especially if the signs are relatively nonspecific. 1 The characteristic rash of skin aGvHD is maculopapular, sometimes pruritic or painful. The distribution is typically on the palms of the hands and soles of the feet, which later progress's to the face, neck, upper chest and trunk. The severe stage III shows generalized erythroderma with progression to bullae formation and desquamation of the epidermal layers of the skin (stage IV-see Figure 2 ).
Acute liver GvHD is characterized by an isolated hyperbilirubinemia. The increase in alkaline phosphatase is seen more frequently than liver enzyme abnormalities.
Gastrointestinal GvHD symptoms are profuse diarrhea accompanied by anorexia and sometimes nausea. Progression with abdominal pain, GI bleeding and ileus is associated with later stages of GvHD (see Figure 3) .
Conclusion
To date, our understanding of the pathogenesis of GvHD has dramatically improved and has led to new modalities of treatment and management. However, it is hoped that as new methodologies evolve and further insights are gained Table 3 Overall clinical grading of aGvHD Grade  Skin  Liver  GI tract  Performance status   0  0  0  0  0  I  1-2  0  0  0  II  1-3  1  1  1  III  2-3  2-3  2-3  2  IV  2- (same patient as Figure 2 ). There is a striking atrophy of the villae, ulceration and bleeding. Biopsy of affected gut may lead to GI tract perforation and/or sepsis. These appearances were associated with severe diarrhea, malabsorption, intestinal ileus and severe pain.
into the underlying risk factors associated with the development of GvHD, it may be possible to construct not only clinical but also genetic paradigms, that may reduce the impact of GvHD as a major cause of transplant morbidity and mortality.
